True Ileal Amino Acid Digestibility of Tenebrio Molitor Larvae in Women

NCT ID: NCT05885191

Last Updated: 2024-04-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

5 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-30

Study Completion Date

2024-04-16

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Dietary protein intake of adequate quality is essential for human health. Traditional animal source foods play a key role in providing high quality protein but are associated with a high burden on the environment. Therefore, viable alternative protein sources are needed to be able to meet human nutritional needs for the rapidly increasing world population, while keeping food production within the planetary boundaries. T. molitor (Yellow Mealworm larvae) is a sustainably produced and commercially available edible insect, which contains a high quantity of protein with a favorable amino acid profile. Protein quality evaluation considers the amino acid composition as well as the ileal digestibility of the food's individual amino acids, to assess if human dietary requirements for essential amino acids can be met by the protein source. The present study will measure the digestibility of essential amino acids from T. molitor with a minimally invasive dual stable isotope tracer method that follows a plateau-fed test meal protocol. T. molitor will be intrinsically labelled with the stable isotope deuterium (2H), which will be given along with a reference amino acid mixture of known digestibility, labelled with the stable isotope carbon-13 (13C). Based on the results from the present study, protein quality of T. molitor as a protein source for human nutrition can be assessed, allowing a direct comparison of this novel protein source to other protein sources, such as meat and legumes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malnutrition; Protein

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

2H intrinsically-labeled T.molitor

1 portion of bread and vegetable soup prepared with dried 2H intrinsically labeled T.molitor and 13C labeled reference amino acid mixture

Group Type EXPERIMENTAL

2H intrinsically-labeled T.molitor with 13-C labeled amino acid mixture

Intervention Type OTHER

Test meal with dried 2H intrinsically labeled T.molitor and 13C labeled reference amino acid mixture will be divided into 10 portions, which will be given hourly over the course of 7 hours. The first consumption will be the priming meal, comprised of 3 portions and will additionally contain 13C sodium bicarbonate.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

2H intrinsically-labeled T.molitor with 13-C labeled amino acid mixture

Test meal with dried 2H intrinsically labeled T.molitor and 13C labeled reference amino acid mixture will be divided into 10 portions, which will be given hourly over the course of 7 hours. The first consumption will be the priming meal, comprised of 3 portions and will additionally contain 13C sodium bicarbonate.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Female aged between 18-45 years
* Normal BMI (18.5 - 25 kg/m2)
* Body weight \< 60 kg
* Signed informed consent
* Able to communicate and comprehend English
* Are open-minded towards consuming insect-based meals

Exclusion Criteria

* Anaemic (Hb \< 12 g/dL)
* Inflammation (CRP \> 5.0 mg/L)
* Pregnancy or intention to become pregnant during the study or within 30 days after the discontinuation of the study intervention
* Lactating up to 6 weeks before the study initiation
* Chronic digestive, renal and/or metabolic diseases
* Antibiotics in the last 4 weeks prior to the study and during the study
* Mineral and vitamin supplementation in the last 2 weeks prior to the study
* Chronic medication intake (except for oral contraceptives)
* Daily exercise routine of high intensity
* Blood transfusion, blood donation or significant blood loss (accident, surgery) over the past 4 months
* Participation in any clinical study within the last 30 days
* Food allergies, especially hypersensitivity to crustacea, dust mites, sea food, gluten, milk, or eggs
* History of serious illness or infection within 3 months of the study
* Cigarette smoking (\> 1 cigarette per day)
* Difficulties with blood or breath sampling
* Participants who cannot be expected to comply with study protocol (e.g., not available for the full 8.5 hours of the study day or unable to follow fasting period)
* Inability to understand the information sheet and the informed consent form due to cognitive or language reasons
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Swiss Distance University of Applied Sciences

OTHER

Sponsor Role collaborator

Swiss Federal Institute of Technology

OTHER

Sponsor Role collaborator

St. John's Research Institute

OTHER

Sponsor Role collaborator

Wageningen University and Research

OTHER

Sponsor Role collaborator

Diego Moretti

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Diego Moretti

Head of Nutrition Research

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Diego Moretti, Prof. Dr.

Role: PRINCIPAL_INVESTIGATOR

Swiss Distance University of Applied Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

ETH Zurich, Laboratory of Human Nutrition

Zurich, , Switzerland

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

TmD01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Fiber Tolerability in Children
NCT02519374 COMPLETED NA
Tolerability of Enteral NAC in Infants
NCT06260566 NOT_YET_RECRUITING PHASE1
The SKyRoCKeT Study
NCT05770817 RECRUITING